Viruses-Basel最新文献

{"title":"Exogenous dsRNA-Mediated RNAi: Mechanisms, Applications, Delivery Methods and Challenges in the Induction of Viral Disease Resistance in Plants.","authors":"Emmadi Venu, Akurathi Ramya, Pedapudi Lokesh Babu, Bhukya Srinivas, Sathiyaseelan Kumar, Namburi Karunakar Reddy, Yeluru Mohan Babu, Anik Majumdar, Suryakant Manik","doi":"10.3390/v17010049","DOIUrl":"10.3390/v17010049","url":null,"abstract":"<p><p>The increasing challenges posed by plant viral diseases demand innovative and sustainable management strategies to minimize agricultural losses. Exogenous double-stranded RNA (dsRNA)-mediated RNA interference (RNAi) represents a transformative approach to combat plant viral pathogens without the need for genetic transformation. This review explores the mechanisms underlying dsRNA-induced RNAi, highlighting its ability to silence specific viral genes through small interfering RNAs (siRNAs). Key advancements in dsRNA production, including cost-effective microbial synthesis and in vitro methods, are examined alongside delivery techniques such as spray-induced gene silencing (SIGS) and nanocarrier-based systems. Strategies for enhancing dsRNA stability, including the use of nanomaterials like layered double hydroxide nanosheets and carbon dots, are discussed to address environmental degradation challenges. Practical applications of this technology against various plant viruses and its potential to ensure food security are emphasized. The review also delves into regulatory considerations, risk assessments, and the challenges associated with off-target effects and pathogen resistance. By evaluating both opportunities and limitations, this review underscores the role of exogenous dsRNA as a sustainable solution for achieving viral disease resistance in plants.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy and COVID-19: Comparing ICU Outcomes for Pregnant and Nonpregnant Women.","authors":"Małgorzata Lipińska-Gediga, Waldemar Goździk, Jakub Śmiechowicz, Barbara Adamik","doi":"10.3390/v17010051","DOIUrl":"10.3390/v17010051","url":null,"abstract":"<p><strong>Background: </strong>This study compares organ dysfunction, treatment strategies, and unfavorable outcome rates between pregnant and nonpregnant women admitted to the ICU with severe COVID-19, highlighting the increased susceptibility of pregnant women to respiratory infections due to physiological changes.</p><p><strong>Methods: </strong>A retrospective, age-matched study was conducted at a referral center specializing in critical care for pregnant women. Data from 14 pregnant/postpartum and 11 nonpregnant women were analyzed at ICU admission and on days 3, 5, and 7.</p><p><strong>Results: </strong>Acute respiratory distress syndrome was diagnosed in 100% of the pregnant/postpartum group and 64% of the nonpregnant group (<i>p</i> = 0.026). Inflammatory parameters were similar between groups, except for lower ferritin levels in the pregnant/postpartum group compared to the nonpregnant (120 vs. 568 µg/L at admission and 90 vs. 616 µg/L on day 3). Creatinine, lactate, and lactate dehydrogenase levels were significantly lower in the pregnant/postpartum group. A reduction in the SOFA score was observed over time in the pregnant/postpartum group (from 7.0 to 4.0 points, <i>p</i> = 0.009), while no change was noticed in the nonpregnant group (from 3.0 to 2.5 points, <i>p</i> = 0.181). Unfavorable outcome rates were similar, with two patients from each group succumbing to the disease (<i>p</i> = 0.604).</p><p><strong>Conclusions: </strong>The findings suggest that pregnancy does not increase the risk of unfavorable outcomes among women with severe COVID-19 receiving ICU treatment. However, additional studies with larger sample sizes are needed to validate these observations.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11768449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dufulin Impacts Plant Defense Against Tomato Yellow Leaf Curl Virus Infecting Tomato.","authors":"Liping Huang, Yingying Tang, Shuaixin Wang, Jianbin Chen, Jiao Du, Shuo Yan, Deyong Zhang, Xiaobin Shi, Yong Liu, Fan Li","doi":"10.3390/v17010053","DOIUrl":"10.3390/v17010053","url":null,"abstract":"<p><p><i>Tomato yellow leaf curl virus</i> (TYLCV) poses a significant threat to tomato production, leading to severe yield losses. The current control strategies primarily rely on the use of pesticides, which are often nonselective and costly. Therefore, there is an urgent need to identify more environmentally friendly alternatives. Dufulin, a novel compound that has been effective in controlling viral diseases in tobacco and rice, has not yet been tested against TYLCV. This study assessed the efficacy of dufulin in controlling TYLCV over a three-year span from 2021 to 2023 through field trials, by monitoring disease symptoms and viral titers. Additionally, this study assessed the expression levels of genes associated with systemic acquired resistance (SAR), specifically <i>proteinase inhibitor II</i> (<i>PI II</i>) and <i>non-expressor of pathogenesis-related genes 1</i> (<i>NPR1</i>), using real-time qRT-PCR. The chlorophyll and nitrogen content in the leaves were also measured. Plants treated with dufulin showed reduced symptomatology and lower viral titers compared to the controls. Analysis of gene expression revealed that <i>NPR1</i> was upregulated in the dufulin-treated plants, whereas <i>PI II</i> expression was consistently downregulated in the TYLCV-infected plants. Interestingly, <i>PI II</i> expression increased in the healthy plants following a seven-day post-treatment with dufulin. Moreover, the treated plants exhibited a higher chlorophyll content than the controls, though no significant differences in the nitrogen levels were observed between the dufulin-treated and water-treated plants. Overall, the application of dufulin significantly bolstered the plant's defense response, effectively reducing TYLCV symptoms and enhancing resistance.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11768724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study.","authors":"Lucio Boglione, Maria Grazia Crobu, Mario Pirisi, Carlo Smirne","doi":"10.3390/v17010040","DOIUrl":"10.3390/v17010040","url":null,"abstract":"<p><p>The effects of a concomitant infection of hepatitis B virus (HBV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are still debated, with a recognized major risk of HBV reactivation during immune-suppressive treatments. The aim of this study was to determine the prevalence and predictive factors of HBV reactivation in a cohort of hospitalized patients with coronavirus disease 2019 (COVID-19) and a current or past hepatitis B infection. In a monocentric retrospective observational study, we enrolled all consecutive hospital admitted patients with COVID-19 pneumonia and a positive HBV serology (N = 84) in our Infectious Diseases Unit from April 2021 to December 2023. We identified 18 (21%) HBsAg-positive/anti-HBc-positive, 41 (49%) HBsAg-negative/anti-HBc-positive/anti-HBs-positive, and 25 (30%) HBsAg-negative/anti-HBc-positive/anti-HBs-negative subjects. The overall rate of hepatitis flare was 10.7%, without any HBsAg seroreversion, severe HBV reactivation, and/or need for new HBV antiviral therapy introduction. Systemic corticosteroid treatment for COVID-19 and baseline anti-HBsAg status were associated with this risk of HBV reactivation. In conclusion, the overall risk of hepatitis flares in hospitalized COVID-19 was reasonably low, with higher doses of corticosteroids treatment being the major risk factor for HBV reactivation, and anti-HBs-positive serological status as a protective element.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of the Utility of Established Cell Lines for Isolation and Propagation of the Southern African Territories Serotypes of Foot-and-Mouth Disease Virus.","authors":"Kitsiso Gaboiphiwe, Tshephang Iris Kabelo, Petronella Thato Mosholombe, Joseph Hyera, Elliot Mpolokang Fana, Kabo Masisi, Kebaneilwe Lebani","doi":"10.3390/v17010039","DOIUrl":"10.3390/v17010039","url":null,"abstract":"<p><p>Cell culture underpins virus isolation and virus neutralisation tests, which are both gold-standard diagnostic methods for foot-and-mouth disease (FMD). Cell culture is also crucial for the propagation of inactivated foot-and-mouth disease virus (FMDV) vaccines. Both primary cells and cell lines are utilised in FMDV isolation and propagation. Widely used cell lines for FMDV and isolation and propagation include baby hamster kidney cells (BHK-21), swine kidney cells (IB-RS-2), foetal goat tongue (ZZ-R 127), foetal porcine kidney cells (LFBKvB6), bovine kidney cells (BK), human telomerase reverse transcriptase bovine thyroid (hTERT-BTY) and porcine kidney-originating PK-15 or SK 6 cell lines. This review highlights how different receptors and molecules-integrins, heparan sulphate (HS), and the Jumonji C-domain containing Protein 6 (JMJD6)-found on the surface of different cell types contribute to differences experienced with susceptibility and sensitivity of the cells to infection with different serotypes of FMDV. This review specifically focuses on Southern African territory (SAT) serotypes, which are unique to the Southern African context and are often under-investigated in cell line development for FMDV isolation and propagation.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11768479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective and Longitudinal Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Positive and Negative Pneumonia: Potential Role of Decreased Naïve CD8⁺ in COVID-19 Patients.","authors":"Makhabbat Bekbossynova, Lyudmila Akhmaltdinova, Kuanysh Dossybayeva, Ainur Tauekelova, Zauresh Smagulova, Tatyana Tsechoeva, Gulsimzhan Turebayeva, Aliya Sailybayeva, Zhanar Kalila, Takhmina Mirashirova, Timur Muratov, Dimitri Poddighe","doi":"10.3390/v17010041","DOIUrl":"10.3390/v17010041","url":null,"abstract":"<p><p><b>Background</b>: During the acute phase of COVID-19, a number of immunological abnormalities have been reported, but few studies longitudinally analyzed the specific subsets of peripheral blood lymphocytes. <b>Methods</b>: In this observational, prospective, and longitudinal study, adult patients developing acute pneumonia during the COVID-19 pandemic have been followed up for 12 months. Peripheral blood lymphocyte subsets were assessed (with a specific focus on the memory markers) at 6 time points after the disease onset until 12 months. <b>Results</b>: A total of 76 patients with acute pneumonia (characterized by a prevalently interstitial pattern of lung inflammation) at the hospital admission (who completed the 12-month follow-up period) were recruited in this study. They were divided into two groups, namely positive (n = 31) and negative (n = 45) patients for the SARS-CoV-2 PCR test. In the acute phase, the general lymphocyte immunophenotyping profile was comparable for most parameters between these groups, except for B cells. When B and T cells were analyzed according to the expression of memory markers, a significant decrease in naïve CD8⁺ T cells was observed in the SARS-CoV-2-positive pneumonia group during the acute phase. Notably, this aspect was maintained during the follow-up period for at least 9 months. <b>Conclusions</b>: COVID-19 pneumonia seems to be associated with a lower number of naïve CD8⁺ T cells compared to pneumonia patients negative for this virus. This alteration can persist in the convalescent phase.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11768816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of HBV Reactivation in Psoriasis Patients Undergoing Cytokine Inhibitor Therapy: A Single-Center Study and Systematic Review with a Meta-Analysis.","authors":"Meng Hsuan Kuo, Ping-Hung Ko, Sz-Tsan Wang, Chih-Wei Tseng","doi":"10.3390/v17010042","DOIUrl":"10.3390/v17010042","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis patients who are seropositive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) face an elevated risk of hepatitis B virus reactivation (HBVr) when treated with cytokine inhibitors. This study aims to elucidate the risk in this population.</p><p><strong>Methods: </strong>A retrospective chart review was conducted to assess the risk of HBVr in 73 psoriasis patients treated with cytokine inhibitors from 2013 to 2023. Additionally, a systematic review and meta-analysis were performed, pooling data from 10 studies (including our cohort) and adhering to PRISMA guidelines. Statistical heterogeneity was assessed using the <i>I</i>² statistic, and pooled proportions were calculated using a random effects model.</p><p><strong>Results: </strong>No HBVr cases were observed among the 11 HBsAg+ patients in the cohort. However, two of the sixty-two (3.2%) HBsAg-/HBcAb+ patients experienced reactivation during therapy, with outcomes ranging from spontaneous recovery in one case to death from hepatic failure despite antiviral treatment in the other. The meta-analysis, pooling data from 10 studies, revealed a reactivation rate of 21.2% (95% CI: 9.4-41.0%) in HBsAg+ patients without prophylaxis and 4.4% (95% CI: 2.2-8.7%) in HBsAg-/HBcAb+ patients.</p><p><strong>Conclusion: </strong>Antiviral prophylaxis is essential for HBsAg+ patients receiving cytokine inhibitors, given the high risk of reactivation. Despite the lower risk for HBsAg-/HBcAb+ patients, the potential severity of outcomes demands careful monitoring and timely action.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Single-Nucleotide Polymorphisms in <i>Toll-like Receptor 3</i> (<i>tlr3</i>), <i>tlr7</i>, <i>tlr8</i> and <i>tirap</i> Genes with Severe Symptoms in Children Presenting COVID-19.","authors":"Adriana Souza Andrade, Aline Almeida Bentes, Lilian Martins Diniz, Silvia Hees Carvalho, Erna Geessien Kroon, Marco Antonio Campos","doi":"10.3390/v17010035","DOIUrl":"10.3390/v17010035","url":null,"abstract":"<p><p>The global number of COVID-19 deaths has reached 7 million, with 4% of these deaths occurring in children and adolescents. In Brazil, around 1500 children up to 11 years old died from the disease. The most common symptoms in children are respiratory, potentially progressing to severe illnesses, such as severe acute respiratory syndrome (SARS) and MIS-C. Studies indicate that comorbidities and genetic factors, such as polymorphisms in immune response genes, can influence the severity of COVID-19. This study investigates the occurrence of single-nucleotide polymorphisms (SNPs) in innate immune response genes in children with COVID-19. Seventy-three samples were analyzed from children under 13 years old hospitalized at João Paulo II Children's Hospital due to COVID-19. The evaluated SNPs were <i>tlr8 (1)</i> (rs3764879), <i>tlr8 (2)</i> (rs2407992), <i>tlr7</i> (rs179008), <i>tlr3</i> (rs3775291), <i>tirap</i> (rs8177374), and <i>mcp-1</i> (rs1024611), considering four categories of severity: mild, moderate, severe, and critical COVID-19. To identify the SNPs, PCR and sequencing were performed. The frequencies of the SNPs obtained were not discrepant when compared to the frequencies described in the Global ALFA, Global 1000 Genomes, Global gnomAD, American 1000 Genomes, and American gnomAD databases, except for the SNP in TLR7. Comparing severe and critical cases to mild and moderate cases, we found a higher relative risk associated with mutations in <i>tlr8 (1)</i>, <i>tlr7</i>, <i>tlr3</i>, and <i>tirap</i> (<i>p</i> < 0.05). No association was found for SNPs in <i>tlr8 (2)</i> and <i>mcp-1</i>. Our analyses suggest an association between SNPs in innate immune response genes and severity of symptoms in children with COVID-19 (or SARS-CoV-2 infected children).</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Ability of Combined Flavonol and Trihydroxyorganic Acid to Suppress SARS-CoV-2 Reproduction.","authors":"Andrey Bogoyavlenskiy, Pavel Alexyuk, Madina Alexyuk, Vladimir Berezin, Irina Zaitseva, Elmira Omirtaeva, Adolat Manakbayeva, Yergali Moldakhanov, Elmira Anarkulova, Anar Imangazy, Kuralay Akanova, Zhumagali Koshemetov, Nurkul Orazymbetova, Bakyt Umuraliyev","doi":"10.3390/v17010037","DOIUrl":"10.3390/v17010037","url":null,"abstract":"<p><p>The global burden of COVID-19 continues to rise, and despite significant progress in vaccine development, there remains a critical need for effective treatments for the severe inflammation and acute lung injury associated with SARS-CoV-2 infection. In this study, we explored the antiviral properties of a plant-derived complex consisting of flavonol and hydroxyorganic acid compounds. Our research focused on the ability of the flavonol and hydroxyorganic acid complex to suppress the activity of several key proteins involved in the replication and maturation of SARS-CoV-2. These proteins include ACE2 protein, HRV 3C Protease, and Mpro (Main Protease). It was shown that the plant-based complex effectively inhibited the activity of these viral proteins. In addition to its effects on viral proteins, the flavonol and hydroxyorganic acid complex were shown to suppress viral replication in Vero E6 cells. At a dose of 22 μg/mL, the drug demonstrated maximum antiviral activity, significantly reducing the replication of SARS-CoV-2 in vitro. In preliminary studies, the complex showed both prophylactic and therapeutic potential, suggesting that it may be useful for preventing infection, as well as reducing the severity of disease once an individual has been infected with SARS-CoV-2. Based on the compelling results of this study, we propose the flavonol and hydroxyorganic acid complex as a potential therapeutic compound for SARS-CoV-2. Its ability to inhibit key viral proteins, suppress viral replication and exhibit protective and therapeutic effects positions it as a valuable candidate for further research and clinical evaluation. As the global fight against SARS-CoV-2 continues, plant-based therapies like this complex could complement existing treatments and provide new options for managing and treating the disease.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143041904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Obesity-Associated SARS-CoV-2 Mutations on COVID-19 Severity and Clinical Outcomes.","authors":"Ana B Martínez-Martinez, Alexander Tristancho-Baró, Beatriz Garcia-Rodriguez, Marina Clavel-Millan, Maria Pilar Palacian, Ana Milagro, Antonio Rezusta, Jose M Arbones-Mainar","doi":"10.3390/v17010038","DOIUrl":"10.3390/v17010038","url":null,"abstract":"<p><p>This study explores the relationship between specific SARS-CoV-2 mutations and obesity, focusing on how these mutations may influence COVID-19 severity and outcomes in high-BMI individuals. We analyzed 205 viral mutations from a cohort of 675 patients, examining the association of mutations with BMI, hospitalization, and mortality rates. Logistic regression models and statistical analyses were applied to assess the impact of significant mutations on clinical outcomes, including inflammatory markers and antibody levels. Our findings revealed three key mutations-C14599T, A20268G, and C313T-that were associated with elevated BMI. Notably, C14599T appeared to be protective against hospitalization, suggesting context-dependent effects, while A20268G was linked to a 50% increase in hospitalization risk and elevated antibody levels, potentially indicating an adaptive immune response. C313T showed a 428% increase in mortality risk, marking it as a possible poor-prognosis marker. Interestingly, all three mutations were synonymous, suggesting adaptive roles in obesity-driven environments despite not altering viral protein structures. These results emphasize the importance of studying mutations within the broader context of comorbidities, other mutations, and regional factors to enhance our understanding of SARS-CoV-2 adaptation in high-risk groups. Further validation in larger cohorts is necessary to confirm these associations and to assess their clinical significance.</p>","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"17 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}